Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nuria Montero

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Pharmaceutics|September 27, 2025
Optimizing Dose Conversion from IR-Tac to LCP-Tac Formulations in Renal Transplant Recipients: A Population Pharmacokinetic Modeling StudyZeyar Mohammed Ali, Beatriz Fernández-Alarcón, Pere Fontova, et al.
Frontiers in Nephrology|November 28, 2024
Nephrology intervention to avoid acute kidney injury in patients awaiting cardiac surgery: randomized clinical trialSergi Codina, Laia Oliveras, Eva Ferreiro, et al.
Kidney Medicine|August 17, 2021
Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant RecipientEdoardo Melilli, Alberto Mussetti, Gabriela Sanz Linares, et al.
Kidney International|June 30, 2023
A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian PredictionNuria Lloberas, Josep M Grinyó, Helena Colom, et al.
Pharmaceutics|May 27, 2023
The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus FormulationsPere Fontova, Lisanne N van Merendonk, Anna Vidal-Alabró, et al.
Clinical Kidney Journal|April 14, 2025
Cancer risks in people on dialysis and kidney transplant recipients: a Catalan cohort study, 2003-21Laia Oliveras, Laura Pareja, Josepa Ribes, et al.
Clinical Pharmacology and Therapeutics|February 24, 2021
Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant RecipientsPere Fontova, Helena Colom, Raül Rigo-Bonnin, et al.
Clinical Kidney Journal|October 7, 2024
Post-transplant renal anemia: a call to action from a national study in routine clinical practiceJose Portoles, Marta Crespo, Miguel Martínez Belotto, et al.
The Journal of Infectious Diseases|June 4, 2019
Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRsHannah Kaminski, Marta Jarque, Mathieu Halfon, et al.
Therapeutic Drug Monitoring|December 8, 2025
Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP FormulationAnna Vidal-Alabró, Pere Fontova, Zeyar Mohammed Ali, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Pharmaceutics|September 27, 2025
Optimizing Dose Conversion from IR-Tac to LCP-Tac Formulations in Renal Transplant Recipients: A Population Pharmacokinetic Modeling StudyZeyar Mohammed Ali, Beatriz Fernández-Alarcón, Pere Fontova, et al.
Frontiers in Nephrology|November 28, 2024
Nephrology intervention to avoid acute kidney injury in patients awaiting cardiac surgery: randomized clinical trialSergi Codina, Laia Oliveras, Eva Ferreiro, et al.
Kidney Medicine|August 17, 2021
Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant RecipientEdoardo Melilli, Alberto Mussetti, Gabriela Sanz Linares, et al.
Kidney International|June 30, 2023
A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian PredictionNuria Lloberas, Josep M Grinyó, Helena Colom, et al.
Pharmaceutics|May 27, 2023
The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus FormulationsPere Fontova, Lisanne N van Merendonk, Anna Vidal-Alabró, et al.
Clinical Kidney Journal|April 14, 2025
Cancer risks in people on dialysis and kidney transplant recipients: a Catalan cohort study, 2003-21Laia Oliveras, Laura Pareja, Josepa Ribes, et al.
Clinical Pharmacology and Therapeutics|February 24, 2021
Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant RecipientsPere Fontova, Helena Colom, Raül Rigo-Bonnin, et al.
Clinical Kidney Journal|October 7, 2024
Post-transplant renal anemia: a call to action from a national study in routine clinical practiceJose Portoles, Marta Crespo, Miguel Martínez Belotto, et al.
The Journal of Infectious Diseases|June 4, 2019
Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRsHannah Kaminski, Marta Jarque, Mathieu Halfon, et al.
Therapeutic Drug Monitoring|December 8, 2025
Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP FormulationAnna Vidal-Alabró, Pere Fontova, Zeyar Mohammed Ali, et al.
Pageof 7